BACKGROUND:Controlled attenuation parameter(CAP) is a non-invasive method for diagnosing hepatic steatosis based on vibration-controlled transient elastography.The objective of this study was to investigate the effect of high value of CAP on antiviral therapy in patients with chronic hepatitis B(CHB).METHODS:Patients with CHB receiving enticavir for initial antiviral therapy were studied;they were divided into the high CAP group and normal CAP group at baseline according to the CAP values.The effect of the antiviral therapy between the two groups were compared at week 12,24 and 48.Patients with high CAP value at baseline were divided into three subgroups,mild,moderate and severe elevation;the therapeutic response were compared among patients with normal CAP and subgroups of patients with elevated CAP.RESULTS:A total of 153 patients were enrolled.Among them,63 were in the high CAP group and 90 in the normal CAP group.Patients with high CAP had lower rates of ALT normalization and HBV DNA clearance in response to antiviral therapy compared with those with normal CAP at week 12,24 and 48.Further analysis showed that the rate of ALT normalization in patients with mildly and moderately elevated CAP were significant lower than those with normal CAP at week 12 and 24;while the difference was not significant between the patients with normal CAP and those with severely elevated CAP.The rate of HBV DNA clearance was significantly lower in patients with severely elevated CAP compared with those with normal CAP at week 12,24 and 48.CONCLUSION:CHB patients with high CAP had poor response to antiviral therapy. BACKGROUND: Controlled attenuation parameter (CAP) is a non-invasive method for diagnosing hepatic steatosis based on vibration-controlled transient elastography. The Objective of this study was to investigate the effect of high value of CAP on antiviral therapy in patients with chronic hepatitis B (CHB). METHODS: Patients with CHB receiving enticavir for initial antiviral therapy were studied; they were divided into the high CAP group and normal CAP group at baseline according to the CAP values. The effect of the antiviral therapy between the two groups were compared at week 12, 24 and 48. Patients with high CAP value at baseline were divided into three subgroups, mild, moderate and severe elevation; the therapeutic response were among patients with normal CAP and subgroups of patients with elevated CAP .RESULTS: A total of 153 patients were enrolled. Among them, 63 were in the high CAP group and 90 in the normal CAP group. Patients with high CAP had lower rates of ALT normalization and HBV DN A clearance in response to antiviral therapy compared with those with normal CAP at week 12, 24 and 48. Further analysis showed that the rate of ALT normalization in patients with mildly and moderately elevated CAP were significantly lower than those with normal CAP at week 12 and 24; while the difference was not significant between the patients with normal CAP and those with severely elevated CAP. Rate of HBV DNA clearance was significantly lower in patients with severely elevated CAP compared to those with normal CAP at week 12, 24 and 48. CONCLUSION: CHB patients with high CAP had poor response to antiviral therapy.